ADVANCE A NOVEL THERAPEUTIC TO A FIRST-IN-HUMAN CLINICAL STUDY
$3,318,955
| Recipient | LOCUS BIOSCIENCES INC UEI CJKVLKZGX6F3 |
|---|---|
| Award ID | 75N93025C00035 |
| Award amount | $3,318,955 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — National Institutes of Health |
| NAICS | 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) |
| PSC | AN12 |
| Start date | Sep 24, 2025 |
| End date | Feb 7, 2029 |
| Place of performance | MORRISVILLE, NC |
| Record updated | Nov 24, 2025 |
View the official award record
More awards won by LOCUS BIOSCIENCES INC
CLINICAL DEVELOPMENT OF CRISPR-CAS3 PHAGE COCKTAIL FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI INCLUDING ANTIMICROBIAL AND MULTI-DRUG RESISTANT STRAINS
Department of Health and Human Services · $48,946,433 · Sep 28, 2020
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids